Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.46M | 66.59M | 67.64M | 71.96M | 72.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.46M | 66.59M | 67.64M | 71.96M | 72.88M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 64.46M | 66.59M | 67.64M | 71.96M | 72.88M |
| SG&A Expenses | 51.33M | 54.18M | 57.85M | 57.96M | 57.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 166.57M | 176.94M | 189.33M | 194.83M | 208.28M |
| Operating Income | -102.11M | -110.35M | -121.69M | -122.87M | -135.40M |
| Income Before Tax | -98.89M | -106.47M | -117.79M | -118.12M | -129.91M |
| Income Tax Expenses | -2.48M | -1.54M | -1.74M | -2.79M | 1.83M |
| Earnings from Continuing Operations | -96.42 | -104.93 | -116.05 | -115.33 | -131.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.42M | -104.93M | -116.05M | -115.33M | -131.74M |
| EBIT | -102.11M | -110.35M | -121.69M | -122.87M | -135.40M |
| EBITDA | -98.94M | -107.77M | -119.36M | -120.34M | -132.81M |
| EPS Basic | -4.54 | -4.95 | -5.49 | -5.46 | -6.25 |
| Normalized Basic EPS | -2.93 | -3.16 | -3.51 | -3.57 | -3.93 |
| EPS Diluted | -4.54 | -4.95 | -5.49 | -5.46 | -6.25 |
| Normalized Diluted EPS | -2.93 | -3.16 | -3.51 | -3.57 | -3.93 |
| Average Basic Shares Outstanding | 84.96M | 84.78M | 84.63M | 84.49M | 84.37M |
| Average Diluted Shares Outstanding | 84.96M | 84.78M | 84.63M | 84.49M | 84.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |